Literature DB >> 16392810

Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.

Xuemei Peng1, Brian I Knapp, Jean M Bidlack, John L Neumeyer.   

Abstract

A series of homo- and heterodimeric ligands containing kappa agonist and mu agonist/antagonist pharmacophores joined by a linker chain of varying lengths was synthesized and evaluated in vitro by their binding affinity at mu, delta, and kappa opioid receptors. The functional activities of these compounds were measured in the [(35)S]GTPgammaS binding assay. The data suggest that the stereochemistry of the pharmacophores, the N-substituents of the pharmacophore, ester linkages, and the spacer length were crucial factors for optimum interactions of such ligands at opioid receptor binding sites. These novel ligands as well as their pharmacological properties will serve as the basis for our continuing investigation of such bivalent ligands as probes of the opioid receptor oligomerization phenomena and for in vivo studies as analgesics.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16392810     DOI: 10.1021/jm050577x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  27 in total

1.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

2.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

3.  High-affinity carbamate analogues of morphinan at opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  Bioorg Med Chem Lett       Date:  2007-01-17       Impact factor: 2.823

4.  New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores.

Authors:  John L Neumeyer; Xuemei Peng; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Severo Salvadori; Claudio Trapella; Gianfranco Balboni
Journal:  J Med Chem       Date:  2006-09-07       Impact factor: 7.446

5.  Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.

Authors:  Xuemei Peng; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2007-04-04       Impact factor: 7.446

Review 6.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

7.  A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic.

Authors:  Severo Salvadori; Claudio Trapella; Stella Fiorini; Lucia Negri; Roberta Lattanzi; Sharon D Bryant; Yunden Jinsmaa; Lawrence H Lazarus; Gianfranco Balboni
Journal:  Bioorg Med Chem       Date:  2007-08-29       Impact factor: 3.641

8.  Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.

Authors:  Brian S Fulton; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  Bioorg Med Chem Lett       Date:  2008-07-17       Impact factor: 2.823

9.  Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.

Authors:  Michael Decker; Brian S Fulton; Bin Zhang; Brian I Knapp; Jean M Bidlack; John L Neumeyer
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

Review 10.  Opioid-receptor-heteromer-specific trafficking and pharmacology.

Authors:  Richard M van Rijn; Jennifer L Whistler; Maria Waldhoer
Journal:  Curr Opin Pharmacol       Date:  2009-10-19       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.